IDEAYA's IDE849 shows early survival data in relapsed lung cancer
Tweet Send to a Friend
IDEAYA Biosciences (Nasdaq: IDYA) announced updated Phase 1 clinical results for IDE849 (SHR-4849), an investigational antibody-drug conjugate targeting DLL3, at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




